0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Vasculitis Drug Market Research Report 2023
Published Date: March 2023
|
Report Code: QYRE-Auto-34F6967
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Vasculitis Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Vasculitis Drug Market Research Report 2023

Code: QYRE-Auto-34F6967
Report
March 2023
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Vasculitis Drug Market

The global Vasculitis Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Vasculitis Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Vasculitis Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Vasculitis Drug include Merck, Bayer, Farmalider, Hainan Pharmaceutical Factory, Shanghaihuangxiang Lantian Pharmaceutical, Huzhou Konch Pharmaceutical, CSPC Ouyi Pharmaceutical, Sino-US Zibo Xinhua-Perrigo Pharmaceutical and Hubei Biocause Pharmaceutical, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vasculitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vasculitis Drug.
The Vasculitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Vasculitis Drug market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vasculitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Key Segmentations

By Company

  • Merck
  • Bayer
  • Farmalider
  • Hainan Pharmaceutical Factory
  • Shanghaihuangxiang Lantian Pharmaceutical
  • Huzhou Konch Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  • Hubei Biocause Pharmaceutical

Segment by Type

  • Blisibimod
  • CCX-168
  • Gevokizumab
  • Rituximab Biosimilar
  • Others

Segment by Application

  • Polyarteritis Nodosa
  • Thrombotic Vasculitis
  • Granulomatous Vasculitis
  • Lymphocytic Vasculitis
  • Others

Consumption by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Vasculitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Vasculitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

Scope of Global Vasculitis Drug Market Report

Report MetricDetails
Report NameGlobal Vasculitis Drug Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Vasculitis Drug Market Overview
1.1 Product Overview and Scope of Vasculitis Drug
1.2 Vasculitis Drug Segment by Type
1.2.1 Global Vasculitis Drug Market Value Comparison by Type (2023-2029)
1.2.2 Blisibimod
1.2.3 CCX-168
1.2.4 Gevokizumab
1.2.5 Rituximab Biosimilar
1.2.6 Others
1.3 Vasculitis Drug Segment by Application
1.3.1 Global Vasculitis Drug Market Value by Application: (2023-2029)
1.3.2 Polyarteritis Nodosa
1.3.3 Thrombotic Vasculitis
1.3.4 Granulomatous Vasculitis
1.3.5 Lymphocytic Vasculitis
1.3.6 Others
1.4 Global Vasculitis Drug Market Size Estimates and Forecasts
1.4.1 Global Vasculitis Drug Revenue 2018-2029
1.4.2 Global Vasculitis Drug Sales 2018-2029
1.4.3 Global Vasculitis Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Vasculitis Drug Market Competition by Manufacturers
2.1 Global Vasculitis Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Vasculitis Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Vasculitis Drug Average Price by Manufacturers (2018-2023)
2.4 Global Vasculitis Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Vasculitis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vasculitis Drug, Product Type & Application
2.7 Vasculitis Drug Market Competitive Situation and Trends
2.7.1 Vasculitis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Vasculitis Drug Players Market Share by Revenue
2.7.3 Global Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Vasculitis Drug Retrospective Market Scenario by Region
3.1 Global Vasculitis Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Vasculitis Drug Global Vasculitis Drug Sales by Region: 2018-2029
3.2.1 Global Vasculitis Drug Sales by Region: 2018-2023
3.2.2 Global Vasculitis Drug Sales by Region: 2024-2029
3.3 Global Vasculitis Drug Global Vasculitis Drug Revenue by Region: 2018-2029
3.3.1 Global Vasculitis Drug Revenue by Region: 2018-2023
3.3.2 Global Vasculitis Drug Revenue by Region: 2024-2029
3.4 North America Vasculitis Drug Market Facts & Figures by Country
3.4.1 North America Vasculitis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Vasculitis Drug Sales by Country (2018-2029)
3.4.3 North America Vasculitis Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Vasculitis Drug Market Facts & Figures by Country
3.5.1 Europe Vasculitis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Vasculitis Drug Sales by Country (2018-2029)
3.5.3 Europe Vasculitis Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vasculitis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Vasculitis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Vasculitis Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Vasculitis Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Vasculitis Drug Market Facts & Figures by Country
3.7.1 Latin America Vasculitis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Vasculitis Drug Sales by Country (2018-2029)
3.7.3 Latin America Vasculitis Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vasculitis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Vasculitis Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Vasculitis Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Vasculitis Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vasculitis Drug Sales by Type (2018-2029)
4.1.1 Global Vasculitis Drug Sales by Type (2018-2023)
4.1.2 Global Vasculitis Drug Sales by Type (2024-2029)
4.1.3 Global Vasculitis Drug Sales Market Share by Type (2018-2029)
4.2 Global Vasculitis Drug Revenue by Type (2018-2029)
4.2.1 Global Vasculitis Drug Revenue by Type (2018-2023)
4.2.2 Global Vasculitis Drug Revenue by Type (2024-2029)
4.2.3 Global Vasculitis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Vasculitis Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Vasculitis Drug Sales by Application (2018-2029)
5.1.1 Global Vasculitis Drug Sales by Application (2018-2023)
5.1.2 Global Vasculitis Drug Sales by Application (2024-2029)
5.1.3 Global Vasculitis Drug Sales Market Share by Application (2018-2029)
5.2 Global Vasculitis Drug Revenue by Application (2018-2029)
5.2.1 Global Vasculitis Drug Revenue by Application (2018-2023)
5.2.2 Global Vasculitis Drug Revenue by Application (2024-2029)
5.2.3 Global Vasculitis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Vasculitis Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Vasculitis Drug Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayer Vasculitis Drug Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Farmalider
6.3.1 Farmalider Corporation Information
6.3.2 Farmalider Description and Business Overview
6.3.3 Farmalider Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Farmalider Vasculitis Drug Product Portfolio
6.3.5 Farmalider Recent Developments/Updates
6.4 Hainan Pharmaceutical Factory
6.4.1 Hainan Pharmaceutical Factory Corporation Information
6.4.2 Hainan Pharmaceutical Factory Description and Business Overview
6.4.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio
6.4.5 Hainan Pharmaceutical Factory Recent Developments/Updates
6.5 Shanghaihuangxiang Lantian Pharmaceutical
6.5.1 Shanghaihuangxiang Lantian Pharmaceutical Corporation Information
6.5.2 Shanghaihuangxiang Lantian Pharmaceutical Description and Business Overview
6.5.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio
6.5.5 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments/Updates
6.6 Huzhou Konch Pharmaceutical
6.6.1 Huzhou Konch Pharmaceutical Corporation Information
6.6.2 Huzhou Konch Pharmaceutical Description and Business Overview
6.6.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio
6.6.5 Huzhou Konch Pharmaceutical Recent Developments/Updates
6.7 CSPC Ouyi Pharmaceutical
6.6.1 CSPC Ouyi Pharmaceutical Corporation Information
6.6.2 CSPC Ouyi Pharmaceutical Description and Business Overview
6.6.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio
6.7.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
6.8 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
6.8.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Corporation Information
6.8.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Description and Business Overview
6.8.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio
6.8.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments/Updates
6.9 Hubei Biocause Pharmaceutical
6.9.1 Hubei Biocause Pharmaceutical Corporation Information
6.9.2 Hubei Biocause Pharmaceutical Description and Business Overview
6.9.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio
6.9.5 Hubei Biocause Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vasculitis Drug Industry Chain Analysis
7.2 Vasculitis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vasculitis Drug Production Mode & Process
7.4 Vasculitis Drug Sales and Marketing
7.4.1 Vasculitis Drug Sales Channels
7.4.2 Vasculitis Drug Distributors
7.5 Vasculitis Drug Customers
8 Vasculitis Drug Market Dynamics
8.1 Vasculitis Drug Industry Trends
8.2 Vasculitis Drug Market Drivers
8.3 Vasculitis Drug Market Challenges
8.4 Vasculitis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Vasculitis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Vasculitis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Vasculitis Drug Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Vasculitis Drug Sales (K Pcs) of Key Manufacturers (2018-2023)
    Table 5. Global Vasculitis Drug Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Vasculitis Drug Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Vasculitis Drug Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Vasculitis Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Vasculitis Drug, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Vasculitis Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Vasculitis Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Vasculitis Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Vasculitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasculitis Drug as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Vasculitis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Vasculitis Drug Sales by Region (2018-2023) & (K Pcs)
    Table 18. Global Vasculitis Drug Sales Market Share by Region (2018-2023)
    Table 19. Global Vasculitis Drug Sales by Region (2024-2029) & (K Pcs)
    Table 20. Global Vasculitis Drug Sales Market Share by Region (2024-2029)
    Table 21. Global Vasculitis Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Vasculitis Drug Revenue Market Share by Region (2018-2023)
    Table 23. Global Vasculitis Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Vasculitis Drug Revenue Market Share by Region (2024-2029)
    Table 25. North America Vasculitis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Vasculitis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 27. North America Vasculitis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 28. North America Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Vasculitis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Vasculitis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Vasculitis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 32. Europe Vasculitis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 33. Europe Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Vasculitis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Vasculitis Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Vasculitis Drug Sales by Region (2018-2023) & (K Pcs)
    Table 37. Asia Pacific Vasculitis Drug Sales by Region (2024-2029) & (K Pcs)
    Table 38. Asia Pacific Vasculitis Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Vasculitis Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Vasculitis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Vasculitis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 42. Latin America Vasculitis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 43. Latin America Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Vasculitis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Vasculitis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Vasculitis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 47. Middle East & Africa Vasculitis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 48. Middle East & Africa Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Vasculitis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Vasculitis Drug Sales (K Pcs) by Type (2018-2023)
    Table 51. Global Vasculitis Drug Sales (K Pcs) by Type (2024-2029)
    Table 52. Global Vasculitis Drug Sales Market Share by Type (2018-2023)
    Table 53. Global Vasculitis Drug Sales Market Share by Type (2024-2029)
    Table 54. Global Vasculitis Drug Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Vasculitis Drug Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Vasculitis Drug Revenue Market Share by Type (2018-2023)
    Table 57. Global Vasculitis Drug Revenue Market Share by Type (2024-2029)
    Table 58. Global Vasculitis Drug Price (USD/Pcs) by Type (2018-2023)
    Table 59. Global Vasculitis Drug Price (USD/Pcs) by Type (2024-2029)
    Table 60. Global Vasculitis Drug Sales (K Pcs) by Application (2018-2023)
    Table 61. Global Vasculitis Drug Sales (K Pcs) by Application (2024-2029)
    Table 62. Global Vasculitis Drug Sales Market Share by Application (2018-2023)
    Table 63. Global Vasculitis Drug Sales Market Share by Application (2024-2029)
    Table 64. Global Vasculitis Drug Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Vasculitis Drug Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Vasculitis Drug Revenue Market Share by Application (2018-2023)
    Table 67. Global Vasculitis Drug Revenue Market Share by Application (2024-2029)
    Table 68. Global Vasculitis Drug Price (USD/Pcs) by Application (2018-2023)
    Table 69. Global Vasculitis Drug Price (USD/Pcs) by Application (2024-2029)
    Table 70. Merck Corporation Information
    Table 71. Merck Description and Business Overview
    Table 72. Merck Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 73. Merck Vasculitis Drug Product
    Table 74. Merck Recent Developments/Updates
    Table 75. Bayer Corporation Information
    Table 76. Bayer Description and Business Overview
    Table 77. Bayer Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 78. Bayer Vasculitis Drug Product
    Table 79. Bayer Recent Developments/Updates
    Table 80. Farmalider Corporation Information
    Table 81. Farmalider Description and Business Overview
    Table 82. Farmalider Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 83. Farmalider Vasculitis Drug Product
    Table 84. Farmalider Recent Developments/Updates
    Table 85. Hainan Pharmaceutical Factory Corporation Information
    Table 86. Hainan Pharmaceutical Factory Description and Business Overview
    Table 87. Hainan Pharmaceutical Factory Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 88. Hainan Pharmaceutical Factory Vasculitis Drug Product
    Table 89. Hainan Pharmaceutical Factory Recent Developments/Updates
    Table 90. Shanghaihuangxiang Lantian Pharmaceutical Corporation Information
    Table 91. Shanghaihuangxiang Lantian Pharmaceutical Description and Business Overview
    Table 92. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 93. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product
    Table 94. Shanghaihuangxiang Lantian Pharmaceutical Recent Developments/Updates
    Table 95. Huzhou Konch Pharmaceutical Corporation Information
    Table 96. Huzhou Konch Pharmaceutical Description and Business Overview
    Table 97. Huzhou Konch Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 98. Huzhou Konch Pharmaceutical Vasculitis Drug Product
    Table 99. Huzhou Konch Pharmaceutical Recent Developments/Updates
    Table 100. CSPC Ouyi Pharmaceutical Corporation Information
    Table 101. CSPC Ouyi Pharmaceutical Description and Business Overview
    Table 102. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 103. CSPC Ouyi Pharmaceutical Vasculitis Drug Product
    Table 104. CSPC Ouyi Pharmaceutical Recent Developments/Updates
    Table 105. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Corporation Information
    Table 106. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Description and Business Overview
    Table 107. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 108. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product
    Table 109. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments/Updates
    Table 110. Hubei Biocause Pharmaceutical Corporation Information
    Table 111. Hubei Biocause Pharmaceutical Description and Business Overview
    Table 112. Hubei Biocause Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 113. Hubei Biocause Pharmaceutical Vasculitis Drug Product
    Table 114. Hubei Biocause Pharmaceutical Recent Developments/Updates
    Table 115. Key Raw Materials Lists
    Table 116. Raw Materials Key Suppliers Lists
    Table 117. Vasculitis Drug Distributors List
    Table 118. Vasculitis Drug Customers List
    Table 119. Vasculitis Drug Market Trends
    Table 120. Vasculitis Drug Market Drivers
    Table 121. Vasculitis Drug Market Challenges
    Table 122. Vasculitis Drug Market Restraints
    Table 123. Research Programs/Design for This Report
    Table 124. Key Data Information from Secondary Sources
    Table 125. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Vasculitis Drug
    Figure 2. Global Vasculitis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Vasculitis Drug Market Share by Type in 2022 & 2029
    Figure 4. Blisibimod Product Picture
    Figure 5. CCX-168 Product Picture
    Figure 6. Gevokizumab Product Picture
    Figure 7. Rituximab Biosimilar Product Picture
    Figure 8. Others Product Picture
    Figure 9. Global Vasculitis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 10. Global Vasculitis Drug Market Share by Application in 2022 & 2029
    Figure 11. Polyarteritis Nodosa
    Figure 12. Thrombotic Vasculitis
    Figure 13. Granulomatous Vasculitis
    Figure 14. Lymphocytic Vasculitis
    Figure 15. Others
    Figure 16. Global Vasculitis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 17. Global Vasculitis Drug Market Size (2018-2029) & (US$ Million)
    Figure 18. Global Vasculitis Drug Sales (2018-2029) & (K Pcs)
    Figure 19. Global Vasculitis Drug Average Price (USD/Pcs) & (2018-2029)
    Figure 20. Vasculitis Drug Report Years Considered
    Figure 21. Vasculitis Drug Sales Share by Manufacturers in 2022
    Figure 22. Global Vasculitis Drug Revenue Share by Manufacturers in 2022
    Figure 23. The Global 5 and 10 Largest Vasculitis Drug Players: Market Share by Revenue in 2022
    Figure 24. Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 25. Global Vasculitis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 26. North America Vasculitis Drug Sales Market Share by Country (2018-2029)
    Figure 27. North America Vasculitis Drug Revenue Market Share by Country (2018-2029)
    Figure 28. U.S. Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Canada Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. Europe Vasculitis Drug Sales Market Share by Country (2018-2029)
    Figure 31. Europe Vasculitis Drug Revenue Market Share by Country (2018-2029)
    Figure 32. Germany Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. France Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. U.K. Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Italy Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Russia Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. Asia Pacific Vasculitis Drug Sales Market Share by Region (2018-2029)
    Figure 38. Asia Pacific Vasculitis Drug Revenue Market Share by Region (2018-2029)
    Figure 39. China Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Japan Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. South Korea Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. India Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Australia Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Taiwan Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Indonesia Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Thailand Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Malaysia Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Philippines Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Latin America Vasculitis Drug Sales Market Share by Country (2018-2029)
    Figure 50. Latin America Vasculitis Drug Revenue Market Share by Country (2018-2029)
    Figure 51. Mexico Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Brazil Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Argentina Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 54. Middle East & Africa Vasculitis Drug Sales Market Share by Country (2018-2029)
    Figure 55. Middle East & Africa Vasculitis Drug Revenue Market Share by Country (2018-2029)
    Figure 56. Turkey Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 57. Saudi Arabia Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 58. UAE Vasculitis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 59. Global Sales Market Share of Vasculitis Drug by Type (2018-2029)
    Figure 60. Global Revenue Market Share of Vasculitis Drug by Type (2018-2029)
    Figure 61. Global Vasculitis Drug Price (USD/Pcs) by Type (2018-2029)
    Figure 62. Global Sales Market Share of Vasculitis Drug by Application (2018-2029)
    Figure 63. Global Revenue Market Share of Vasculitis Drug by Application (2018-2029)
    Figure 64. Global Vasculitis Drug Price (USD/Pcs) by Application (2018-2029)
    Figure 65. Vasculitis Drug Value Chain
    Figure 66. Vasculitis Drug Production Process
    Figure 67. Channels of Distribution (Direct Vs Distribution)
    Figure 68. Distributors Profiles
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS